Tisch MS News

Tune in to The Dr. Oz Show this Thursday, December 12th to see Dr. Sadiq as a featured guest along with his patient Richard Cohen and Richard's spouse Meredith Vieira. Richard and Meredith will be discussing living with MS and their hopes for our recently approved FDA Phase I Stem Cell Clinical...

December 10, 2013


Dr. Steven A. Goldman, MD, PhD, Co-Director of the Center for Translational Medicine and Professor in the Departments of Neurology and Neurosurgery at the University of Rochester School of Medicine and Dentistry, delivered the Grand Rounds lecture for December 4, 2013. Dr. Goldman's presentation...

December 4, 2013


Tisch MS Research Center of New York would like to advise patients and other interested parties that we will be closing at 2pm on Wednesday, November 27, and reopening on Monday, December 2, in observance of the Thanksgiving holiday.

November 22, 2013


Tisch MSRCNY welcomed almost 1,000 guests on Sunday, October 13, 2013 to the New York Hilton. We would like to thank our patients and supporters for making this a truly momentous event! The title of Dr. Sadiq’s talk, “What Does This Study Mean For Me?” signified an opportunity to answer many...

October 17, 2013


Multiple Sclerosis Journal has selected the recent Tisch MS publication " Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis ," co-authored by Violaine Harris, PhD, and Saud Sadiq, MD, among others, as its cover article for October 2013. This important biomarker discovery is...

September 24, 2013


Ricki Lewis, Ph.D., filed a report for the Multiple Sclerosis Discovery Forum on FDA approval for the upcoming clinical trial of MSC-NPs at the Tisch MS Research Center of New York. Lewis quotes multiple outside experts alongside Saud Sadiq, M.D., director of Tisch MS, on the science behind the...

September 16, 2013


The stem cell research division of the Tisch MS Research Center of New York proudly announces Food and Drug Administration (FDA) approval of autologous, mesenchymal stem cell-derived neural progenitor cells (MSC-NPs) as an Investigational New Drug (IND) for an open label, phase I clinical trial in...

August 14, 2013


A Research team lead by Violaine Harris, Ph.D., at the Tisch MS Research Center of New York, has just published findings on a new method of measuring disease activity in patients with multiple sclerosis (MS) (Harris, et al, Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis,...

July 26, 2013


Tisch MS Research Center of New York has formally submitted a response to the Food and Drug Administration’s (FDA) clinical hold on our proposed Phase I trial of Mesenchymal Stem Cell-Derived Neural Progenitors in the treatment of multiple sclerosis. Per agency rules, this submission necessitates a...

July 15, 2013


Violaine Harris (Tisch MSRCNY) presented the following article in Journal Club. Article Title: A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis Reference: S.D. Shields, PhD, X. Cheng, PhD, A. Gasser, PhD, C.Y. Saab, PhD, L. Tyrrell, MS, E.M. Eastman, BS, M...

July 12, 2013



Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy


Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.